SCHEMBL3924682

SCHEMBL3924682

OCC(CO)OC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 1/20 0.56
PRKCG P05129 1/20 0.56
PRKCB P05771 1/20 0.56
PRKCA P17252 1/20 0.56
PRKCH P24723 1/20 0.56
PRKCI P41743 1/20 0.56
PRKCE Q02156 1/20 0.56
PRKCQ Q04759 1/20 0.56
PRKCZ Q05513 1/20 0.56
PRKCD Q05655 1/20 0.56
PRKD1 Q15139 1/20 0.56
CD209 Q9NNX6 3/20 0.51
SYNJ2 O15056 2/20 0.50
GAA P10253 2/20 0.50
KDM4E B2RXH2 1/20 0.50
ABL1 P00519 1/20 0.50
ALPL P05186 1/20 0.50
POLB P06746 1/20 0.50
ALPI P09923 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16186721 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL8254322 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL18328428 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL1923753 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL14217500 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL2300084 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL13851827 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL3516599 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL12030336 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL5545675 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180080057-A1 DIAGNOSIS OF BACTERIAL VAGINOSIS LONDON HEALTH SCI CT RES INC 2018-03-22 US claimed
WO-2016161525-A1 DIAGNOSIS OF BACTERIAL VAGINOSIS REID GREGOR (CA) 2016-10-13 WO claimed
CN-114868954-A Tobacco humectant and method for improving tobacco moistening feeling 上海龙殷生物科技有限公司 2022-08-09 CN disclosed
US-10934573-B2 Diagnosis of bacterial vaginosis LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) 2021-03-02 US disclosed
US-20180080057-A1 DIAGNOSIS OF BACTERIAL VAGINOSIS LONDON HEALTH SCI CT RES INC 2018-03-22 US disclosed
EP-1652435-B1 Use of red algae subjected to extreme temperature and light conditions. EXSYMOL SA (MC) 2017-06-14 EP disclosed
WO-2016161525-A1 DIAGNOSIS OF BACTERIAL VAGINOSIS REID GREGOR (CA) 2016-10-13 WO disclosed
EP-1453844-B1 USE OF GLYCOSIDES OF MONO- AND DIACYLGLYCEROL AS ANTI-INFLAMMATORY AGENTS UNIV AARHUS (DK) 2013-11-20 EP disclosed
US-7483812-B2 Method for determining a linear relationship from measured data that can be stored electronically UNIVERSITAT POTSDAM (DE) 2009-01-27 US disclosed
US-7084122-B2 Use of glycosides of mono- and diacyglycerol as anti-inflammatory agents UNIVERSITY OF COPENHAGEN (DK) 2006-08-01 US disclosed
EP-1652435-A1 Use of red algae subjected to extreme temperature and light conditions. EXSYMOL S.A.M. (MC) 2006-05-03 EP disclosed
US-20060015307-A1 Method for determining a linear relationship from measured data that can be stored electronically UNIVERSITAT POTSDAM (DE) 2006-01-19 US disclosed
US-20050049205-A1 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents UNIVERSITY OF COPENHAGEN (DK) 2005-03-03 US disclosed
EP-1453844-A2 USE OF GLYCOSIDES OF MONO- AND DIACYLGLYCEROL AS ANTI-INFLAMMATORY AGENTS Danmarks Jordbrugsforskning (DK) 2004-09-08 EP disclosed
US-20030139350-A1 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents UNIVERSITY OF COPENHAGEN (DK) 2003-07-24 US disclosed
WO-2003043613-A2 USE OF GLYCOSIDES OF MONO- AND DIACYLGLYCEROL AS ANTI-INFLAMMATORY AGENTS DANMARKS JORDBRUGSFORSKNING (DK) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049205-A1 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents DGKZ, DGKG, DAGLA PRKD3 720/4885PRKCG 701/4885PRKCB 1476/4885
US-20030139350-A1 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents DGKZ, DGKG, DGKK PRKD3 712/4885PRKCG 757/4885PRKCB 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.